Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 850
- Registration Number
- NCT06356129
- Locations
- 🇺🇸
Cancer Care Specialists, Reno, Nevada, United States
🇺🇸Local Institution - 0498, East Brunswick, New Jersey, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 43
- Registration Number
- NCT06350318
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 600
- Registration Number
- NCT06337318
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Helen F Graham Cancer Center, Newark, Delaware, United States
Ma-Spore ALL 2020 Study
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT06336395
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Istituto Clinico Humanitas
- Target Recruit Count
- 37
- Registration Number
- NCT06325943
- Locations
- 🇮🇹
IRCCS Istituto Clinico Humanitas, Rozzano, Italy
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT06319456
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 790
- Registration Number
- NCT06284122
- Locations
- 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT06265220
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸University of California, San Diego, San Diego, California, United States
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06263491
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.